News & Blogs

Jon Decker: Why Build Back Better’s prescription price controls are a bad idea

Joe Biden’s “Build Back Better” nonsense is getting a boost from an extremely powerful and well-funded lobbying force — AARP — and it’s time for us to call them out on it. The so-called “seniors advocacy organization” has been pushing hard for the passage of Biden’s massive, inflation-inducing spending bill. Why? Because the House version of the bill would have the federal government set the price of prescription drugs under the guise of “negotiation.” If…

Learn More

On Build Back Better and Gasoline: Why Price Controls Are Always A Bad Idea

Biden’s “Build Back Better” nonsense is getting a boost from an extremely powerful and well-funded lobbying force—the AARP—and it’s time for us to call them out on it. The so-called “seniors advocacy organization” has been pushing hard for the passage of Biden’s massive, inflation-inducing spending bill. Why? Because the House version of the bill would have the federal government set the price of prescription drugs under the guise of “negotiation.” If the bill were enacted,…

Learn More

Newt Gingrich: Democrats say they are the party of science but their drug price plans tell a different story

The Democrats like to present themselves as the party of science, but two recent announcements show just how ignorant they are about how science moves from the lab into our medicine cabinet. The first announcement was results from Pfizer’s clinical trial of its new anti-viral treatment for COVID-19. The treatment reduced hospital admissions in high-risk individuals by a stunning 90 percent compared to those receiving a placebo. Even more remarkably, not a single person receiving…

Learn More

During this Year’s Medicare Open Enrollment, Don’t Assume AARP Has Your Best Interests in Mind

Millions of seniors are considering their options during this year’s Medicare open enrollment period, which is underway through December 7. Before making this important decision, though, seniors should do their research. This is especially true if they are considering an AARP-promoted Medicare Advantage or Medigap plan. Currently, AARP maintains an exclusive relationship with UnitedHealthcare (UHC)—meaning they only sell plans carried by that insurance giant. However, these plans are overpriced when purchased through AARP. So why,…

Learn More

Richard Berman: Drug pricing proposal is another exercise in Washington short-sightedness

Policymakers often create long-term harm while chasing short-term rewards. Running up the national debt creates electoral goodwill now because people like free stuff. In the long run, debt service payments will increasingly crowd out other spending priorities. Eventually, the music stops. The feedback loop created by guaranteed government-backed college loans and subsidies is similar. Although net tuition costs are temporarily reduced, the guarantee of student aid incentivizes universities to raise the price of admission higher,…

Learn More

Phil Kerpen: Drug Price Controls Would Hurt Seniors

The latest iteration of Build Back Better – the president’s multi-trillion-dollar tax-and-spending binge that has been stalled in Congress all year – purports to reduce the cost of prescription drugs via negotiation. Medicare prescription drug plans already negotiate prices aggressively. As Obama’s CBO director Doug Elmendorf explained back in 2009: “additional authority to negotiate for lower drug prices would have little, if any, effect on prices for the same reason that my predecessors have explained,…

Learn More

WSJ Editorial Board: A Toxic Drug-Price Deal

So much for self-reflection after a political drubbing. Democrats are responding to last week’s defeat by rushing President Biden’s spending framework through the House while rewriting it on the fly—and they’ll worry about the consequences later. Consider the latest compromise to reduce drug prices, which will do the opposite. Progressives hope that passing legislation in the name of lower prices will increase senior support for their spending bill. But some House Democrats balked at earlier…

Learn More

Dan Leonard: The hurried push by Congress to address drug costs shouldn’t undermine the vast savings from generics and biosimilars

Americans rightfully expect Congress to address the ever-increasing prices of brand-name prescription drugs. But the wholesale policy changes now under rushed consideration in Congress will undermine the only proven solution to this long-standing problem: competition from Food and Drug Administration-approved generic and biosimilar medicines. Generic and biosimilar medicines generated $2 trillion in savings to the U.S. health care system over the last decade. Yet proposals in the reconciliation package will jeopardize the development of these less-expensive drugs, harming…

Learn More